It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Chronic stimulation of CD8+ T cells triggers exhaustion, a distinct differentiation state with diminished effector function. Exhausted cells exist in multiple differentiation states, from stem-like progenitors that are the key mediators of the response to checkpoint blockade, through to terminally exhausted cells. Due to its clinical relevance, there is substantial interest in defining the pathways that control differentiation and maintenance of these subsets. Here, we show that chronic antigen induces the anergy-associated transcription factor EGR2 selectively within progenitor exhausted cells in both chronic LCMV and tumours. EGR2 enables terminal exhaustion and stabilizes the exhausted transcriptional state by both direct EGR2-dependent control of key exhaustion-associated genes, and indirect maintenance of the exhausted epigenetic state. We show that EGR2 is a regulator of exhaustion that epigenetically and transcriptionally maintains the differentiation competency of progenitor exhausted cells.
Exhausted T cells arise when chronic activation triggers functional defects. Here the authors show that chronic antigenic stimulation in both tumour and infection models induces the expression of EGR2, which drives and stabilises exhausted cell epigenetic and transcriptional identity.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details











1 Australian National University, John Curtin School of Medical Research, ACT, Australia (GRID:grid.1001.0) (ISNI:0000 0001 2180 7477)
2 Peter MacCallum Cancer Centre, Melbourne, Australia (GRID:grid.1055.1) (ISNI:0000000403978434); University of Melbourne, Sir Peter MacCallum Department of Oncology, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)
3 Peter MacCallum Cancer Centre, Melbourne, Australia (GRID:grid.1055.1) (ISNI:0000000403978434)
4 The Kirby Institute for Infection and Immunity, UNSW, Sydney, Australia (GRID:grid.1005.4) (ISNI:0000 0004 4902 0432); University of New South Wales, Faculty of Medicine, Sydney, Australia (GRID:grid.1005.4) (ISNI:0000 0004 4902 0432)
5 Garvan Institute of Medical Research, Darlinghurst, Australia (GRID:grid.415306.5) (ISNI:0000 0000 9983 6924); University of New South Wales, Sydney, Australia (GRID:grid.1005.4) (ISNI:0000 0004 4902 0432)
6 University of Melbourne, Centre for Cancer Research, VCCC, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)
7 The University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); The University of Melbourne, Department of Microbiology and Immunology, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia (GRID:grid.1042.7)
8 The University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); The University of Melbourne, Department of Microbiology and Immunology, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)
9 Peter MacCallum Cancer Centre, Melbourne, Australia (GRID:grid.1055.1) (ISNI:0000000403978434); University of Melbourne, Sir Peter MacCallum Department of Oncology, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); Monash University, Department of Immunology, Central Clinical School, Melbourne, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857)
10 Johns Hopkins University of Medicine, Bloomberg~Kimmel Institute for Cancer Immunotherapy, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311)
11 Australian National University, John Curtin School of Medical Research, ACT, Australia (GRID:grid.1001.0) (ISNI:0000 0001 2180 7477); University of New South Wales, Faculty of Medicine, Sydney, Australia (GRID:grid.1005.4) (ISNI:0000 0004 4902 0432); Garvan Institute of Medical Research, Darlinghurst, Australia (GRID:grid.415306.5) (ISNI:0000 0000 9983 6924)
12 Australian National University, John Curtin School of Medical Research, ACT, Australia (GRID:grid.1001.0) (ISNI:0000 0001 2180 7477); Peter MacCallum Cancer Centre, Melbourne, Australia (GRID:grid.1055.1) (ISNI:0000000403978434); University of Melbourne, Sir Peter MacCallum Department of Oncology, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)